At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 20 enrolled
Drug / intervention
Spinal cord stimulation systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Spinal Cord Stimulation For Heart Failure As A Restorative Treatment
In Brief
A Phase 3 clinical trial evaluating Spinal cord stimulation system for Systolic Heart Failure. Completed, enrolled 20 participants across 5 sites in 3 countries.
Detailed Summary
The primary objectives of this feasibility study are to determine the safety of spinal cord stimulation (SCS) as a therapy in patients with systolic heart failure and to gather observational information for potential efficacy markers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystolic Heart Failure
CountriesAustralia, Hong Kong, Japan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedMay 2011
Primary CompletionAug 2014
Study CompletionJan 2016
TodayJul 2026
First PostedMay 30, 2011
Enrollment StartApr 1, 2011
Primary CompletionAug 1, 2014
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.1 years ago
Interventions
Spinal cord stimulation systemdevice
An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.